Humanwell Healthcare (Group)Ltd Beheer

Beheer criteriumcontroles 2/4

De CEO Humanwell Healthcare (Group)Ltd is Xiafei Deng, benoemd in Jun2020, heeft een ambtstermijn van 4.42 jaar. bezit rechtstreeks 0.098% van de aandelen van het bedrijf, ter waarde CN¥ 35.38M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 4.6 jaar en 9 jaar.

Belangrijke informatie

Xiafei Deng

Algemeen directeur

CN¥7.2m

Totale compensatie

Percentage CEO-salaris	n/a
Dienstverband CEO	4.4yrs
Eigendom CEO	0.1%
Management gemiddelde ambtstermijn	4.6yrs
Gemiddelde ambtstermijn bestuur	9yrs

Recente managementupdates

Recent updates

CEO

Xiafei Deng (60 yo)

4.4yrs

Tenure

CN¥7,185,300

Compensatie

Mr. Xiafei Deng serves as President at Humanwell Healthcare (Group) Co.,Ltd. since June 2020. He serves as Director of Wuhan Humanwell Healthcare (Group) Co.,Ltd.and served as its Vice President until Jun...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Xiafei Deng	President & Director	4.4yrs	CN¥7.19m	0.098% CN¥ 35.4m
Yajun Wu	CFO & VP	20.7yrs	CN¥2.08m	0.059% CN¥ 21.5m
Qianlun Li	VP & Secretary	11.5yrs	CN¥1.97m	0.019% CN¥ 6.7m
Wentao Du	Vice President	21.1yrs	CN¥4.07m	0.056% CN¥ 20.2m
Lie Li	Vice President	4.6yrs	CN¥3.70m	0.032% CN¥ 11.5m
Hongjie Zhang	Vice President	no data	CN¥4.97m	0.028% CN¥ 10.1m
Qiang Yin	Vice President	4.6yrs	CN¥1.97m	0.028% CN¥ 10.1m
Qun Yu	Vice President	4.1yrs	CN¥3.69m	0.028% CN¥ 10.1m

4.6yrs

Gemiddelde duur

54.5yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van 600079 wordt beschouwd als ervaren (gemiddelde ambtstermijn 4.6 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Xiafei Deng	President & Director	25.8yrs	CN¥7.19m	0.098% CN¥ 35.4m
Min Qi	Supervisor	10.5yrs	geen gegevens	geen gegevens
Rui Zhou	Independent Director	3.5yrs	CN¥100.00k	geen gegevens
Lin Qing Liu	Independent director	4.5yrs	CN¥100.00k	geen gegevens
Xiao Dong Zhang	Director	27.8yrs	CN¥1.81m	0.029% CN¥ 10.4m
Xuehai Wang	Director	21.5yrs	CN¥618.50k	0.22% CN¥ 81.3m
Jie Li	Chairman of the Board	21.5yrs	CN¥5.67m	5.39% CN¥ 2.0b
Yue Xin Du	Chairman of the Supervisory Board	19.7yrs	CN¥66.00k	geen gegevens
Hansheng Zhou	Director	7.6yrs	CN¥1.81m	geen gegevens
Chenggang Zheng	Supervisor	4.5yrs	geen gegevens	geen gegevens
Kong Na	Representative Member of the Supervisory Board	4.5yrs	geen gegevens	geen gegevens
Xia Yuan	Employee Representative Member of the Supervisory Board	4.5yrs	geen gegevens	geen gegevens

9.0yrs

Gemiddelde duur

55yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van 600079 wordt beschouwd als ervaren (gemiddelde ambtstermijn 9 jaar).

Humanwell Healthcare (Group)Ltd Beheer

Beheer criteriumcontroles 2/4

Belangrijke informatie

Recente managementupdates

Humanwell Healthcare (Group) Co.,Ltd., Annual General Meeting, Apr 25, 2024

Less than half of directors are independent

Less than half of directors are independent

Recent updates

Third quarter 2024 earnings released: EPS: CN¥0.30 (vs CN¥0.27 in 3Q 2023)

Upcoming dividend of CN¥0.15 per share

Humanwell Healthcare (Group) Co.,Ltd. to Report Q3, 2024 Results on Oct 30, 2024

Investor sentiment improves as stock rises 21%

Investor sentiment deteriorates as stock falls 16%

Second quarter 2024 earnings released: EPS: CN¥0.38 (vs CN¥0.41 in 2Q 2023)

Humanwell Healthcare (Group) Co.,Ltd. to Report First Half, 2024 Results on Aug 15, 2024

Dividend of CN¥0.46 announced

First quarter 2024 earnings released: EPS: CN¥0.30 (vs CN¥0.41 in 1Q 2023)

Full year 2023 earnings released: EPS: CN¥1.32 (vs CN¥1.54 in FY 2022)

Humanwell Healthcare (Group) Co.,Ltd., Annual General Meeting, Apr 25, 2024

Investor sentiment improves as stock rises 17%

Humanwell Healthcare (Group) Co.,Ltd. to Report Fiscal Year 2023 Results on Mar 29, 2024

Third quarter 2023 earnings released: EPS: CN¥0.27 (vs CN¥0.42 in 3Q 2022)

Second quarter 2023 earnings released: EPS: CN¥0.41 (vs CN¥0.35 in 2Q 2022)

Full year 2022 earnings released: EPS: CN¥1.54 (vs CN¥0.83 in FY 2021)

Less than half of directors are independent

Third quarter 2022 earnings released: EPS: CN¥0.42 (vs CN¥0.27 in 3Q 2021)

Investor sentiment improved over the past week

Second quarter 2022 earnings released: EPS: CN¥0.41 (vs CN¥0.23 in 2Q 2021)

Investor sentiment improved over the past week

First quarter 2022 earnings released: EPS: CN¥0.58 (vs CN¥0.19 in 1Q 2021)

Less than half of directors are independent

Novo Holdings A/S agreed to acquire The Ritedose Corporation from AGIC Capital, Humanwell Healthcare (Group) Co.,Ltd. (SHSE:600079) and others.

Third quarter 2021 earnings released: EPS CN¥0.27 (vs CN¥0.16 in 3Q 2020)

Second quarter 2021 earnings released: EPS CN¥0.23 (vs CN¥0.19 in 2Q 2020)

Investor sentiment improved over the past week

First quarter 2021 earnings released: EPS CN¥0.19 (vs CN¥0.10 in 1Q 2020)

Investor sentiment improved over the past week

New 90-day low: CN¥26.05

Investor sentiment improved over the past week

New 90-day low: CN¥27.26

New 90-day low: CN¥30.20

Humanwell Healthcare (Group) Co.,Ltd. to Report Q3, 2020 Results on Oct 26, 2020

New 90-day low: CN¥30.82

Humanwell Healthcare (Group) Co.,Ltd. (SHSE:600079) entered into a preliminary letter of intent to acquire an additional 13% stake in YiChang Humanwell Pharmaceutical Co., Ltd from Li Jie, Chen Xiaoqing, and Xu Huabin.

New 90-day high - CN¥38.00

Chongqing Pharmaceutical (Group) Co., Ltd. signed the Sichuan Humanwell Pharmaceutical Co., Ltd. Equity Transfer Contract to acquire 70% stake in Sichuan Humanwell Pharmaceutical Co., Ltd from Humanwell Healthcare (Group) Co.,Ltd. (SHSE:600079) for approximately CNY 360 million.

New 90-day high - CN¥36.59

Humanwell Healthcare (Group) Co.,Ltd. to Report First Half, 2020 Results on Aug 22, 2020

CEO

Tenure

Compensatie

Leiderschapsteam

Gemiddelde duur

Gemiddelde leeftijd

Bestuursleden

Gemiddelde duur

Gemiddelde leeftijd